Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2022 | Recent developments in Parkinson’s disease

Francisco Cardoso, MD, PhD, FAAN, The Federal University of Minas Gerais, Belo Horizonte, Brazil, and President of the International Parkinson and Movement Disorder Society (MDS), reviews the most critical developments in the field of Parkinson’s disease in 2022. Over the last years, the expectation surrounding anti-α-synuclein therapies grew significantly, however, clinical trial updates shared throughout this year have shown unsuccessful results. Nevertheless, important progress is being made in the genetics area, where a better understanding of the genes involved in Parkinson’s disease is leading to the development of personalized therapies. This interview took place at the 2022 International Congress of Parkinson’s disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.